[The use of neuron specific enolase in the prognosis and followup of neuroblastoma in children. Results of a retrospective series of 21 patients].
OBJECTIVE
To report the results of seric neuron specific enolase in pediatric neuroblastoma.


METHODS
Our retrospective study concerns 21 children treated in our institution from 1992 to 1998 for neuroblastoma. Seric NSE was determined by immunoenzymology technique at different stages of the disease and the treatment.


RESULTS
Mean value for the 39 dosages of the whole patients was 127.9 ng/ml with a sensitivity of 56%, five patients has presented normal values. Mean value for the 18 patients in stage IV was 132.38 ng/ml. We also observed in 3 patients, an evolution of the seric NSE parallel to this of the disease under chemotherapy.


CONCLUSIONS
NSE represents a moderate sensitive and specific tumor marker for pediatric neuroblastoma. However, it represents a good value in prognosis and follow-up after chemotherapy.
Abdennebi
M
M
Service de biologie clinique, Institut Salah Azaïz.
Boussen
H
H
Harzallah
L
L
Daldoul
O
O
Ghanem
A
A
Gamoudi
A
A
Ben Slimene
F
F
Rahal
K
K
el May
A
A
Ben Ayed
F
F
Guemira
F
F
D014408:Biomarkers, Tumor / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D007223:Infant; D008297:Male; D009367:Neoplasm Staging; D009447:Neuroblastoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D010751:Phosphopyruvate Hydratase / Q000097:blood*; D011379:Prognosis; D012189:Retrospective Studies; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; D010751:Phosphopyruvate Hydratase